Anterior Nucleus of the Thalamus Ablation Combined with Anterior Two-Thirds Corpus Callosotomy Stereotactic Ablation in Patients with Temporal Lobe Epilepsy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511752044451

Enrollment

Registered

2025-11-06

Start date

2025-11-08

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases

Interventions

Anterior nucleus of the thalamus ablation

Anterior nucleus of the thalamus ablation with anterior two thirds corpus callosotomy stereotactic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Age from 18 to 65 years. • Both sexes. • Patients with temporal lobe epilepsy (TLE). • Documented drug-resistant epilepsy (failure of =2 appropriately chosen and adequately dosed antiepileptic drugs).

Exclusion criteria

Exclusion criteria: • Severe comorbid medical or psychiatric illness contraindicating surgery. • Prior thalamic or callosal surgery. • Cognitive impairment. • Structural brain abnormalities precluding stereotactic navigation.

Design outcomes

Primary

Measure	Time frame
Seizure reduction	—

Secondary

Measure	Time frame
Responder rate;Incidence of complications	—

Countries

Egypt

Contacts

Public ContactAhmed Taha

Assistant Professor

ahmed.taha.abdella.1980@gmail.com01148048480

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026